Scholarlink

Purpose <p>The assessment of the lung shunting fraction (LSF) in yttrium-90 (<sup>90</sup>Y) or holmium-166 (<sup>166</sup>Ho) transarterial radioembolization (TARE) is customary in order to reduce the risk of radiation pneumonitis (RP). Lung shunting detected through a test dose is considered a relative contraindication, and it is generally advised to keep the predicted lung dose below 30&#xa0;Gy. Few cases of RP have been reported in the literature. We present two cases of RP after treatment with <sup>166</sup>Ho TARE.</p> Methods <p>Two patients with hepatocellular carcinoma received <sup>166</sup>Ho TARE, respectively as part of a clinical trial and a re-treatment according to standard clinical practise. LSF and lung dose measurements were performed both after the work-up and after the therapeutic dose using planar imaging and SPECT. At follow up, CT imaging and pulmonary evaluation including lung function testing were performed.</p> Results <p>Two patients without any pulmonary medical history received a lung dose of 13&#xa0;Gy and 18&#xa0;Gy due to a LSF of 9.8% and 7.1% based on SPECT after therapy. The patients showed both clinical and radiological signs of RP which resolved 3–4 months after TARE. Lung function testing showed no restriction or obstruction, but did show lowered diffusion.</p> Conclusion <p>We present two relatively mild cases of RP after <sup>166</sup>Ho TARE, with a lung dose under the advised lung dose threshold of 30&#xa0;Gy. Although no definite conclusions can be drawn based on these isolated cases of RP, it warrants caution in pre-treatment dosimetry in case of objectified lung shunt.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Lung shunting and radiation pneumonitis after holmium-166 TARE: a case study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月8日

查看全文
  • Meike W. M. van Wijk,
  • Marcel J. R. Janssen,
  • Mark J. Arntz,
  • Bram H. J. Geurts,
  • Laura A. Michon,
  • Eric T. T. L. Tjwa,
  • Joey Roosen,
  • J. Frank W. Nijsen

摘要

Purpose

The assessment of the lung shunting fraction (LSF) in yttrium-90 (90Y) or holmium-166 (166Ho) transarterial radioembolization (TARE) is customary in order to reduce the risk of radiation pneumonitis (RP). Lung shunting detected through a test dose is considered a relative contraindication, and it is generally advised to keep the predicted lung dose below 30 Gy. Few cases of RP have been reported in the literature. We present two cases of RP after treatment with 166Ho TARE.

Methods

Two patients with hepatocellular carcinoma received 166Ho TARE, respectively as part of a clinical trial and a re-treatment according to standard clinical practise. LSF and lung dose measurements were performed both after the work-up and after the therapeutic dose using planar imaging and SPECT. At follow up, CT imaging and pulmonary evaluation including lung function testing were performed.

Results

Two patients without any pulmonary medical history received a lung dose of 13 Gy and 18 Gy due to a LSF of 9.8% and 7.1% based on SPECT after therapy. The patients showed both clinical and radiological signs of RP which resolved 3–4 months after TARE. Lung function testing showed no restriction or obstruction, but did show lowered diffusion.

Conclusion

We present two relatively mild cases of RP after 166Ho TARE, with a lung dose under the advised lung dose threshold of 30 Gy. Although no definite conclusions can be drawn based on these isolated cases of RP, it warrants caution in pre-treatment dosimetry in case of objectified lung shunt.